Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2022-11-11 Interim / Quarterly Rep…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JAN-SEP 2022' (Interim Report Jan-Sep 2022) for Nanologica AB. It contains comprehensive financial statements, key performance indicators (Nyckeltal), management commentary (VD har ordet), and detailed business segment analysis for the period. It is clearly a quarterly/interim financial report, not an announcement of a report or a simple regulatory filing. 9M 2022
2022-11-11 Swedish
Nanologicas företrädesemission registrerad – omvandling av BTA till aktier
Capital/Financing Update Classification · 98% confidence The document is a press release dated November 8, 2022, announcing that Nanologica AB's rights issue (företrädesemission) has been registered with the Swedish Companies Registration Office (Bolagsverket). It details the subscription rate (85%), the capital raised (79.8 MSEK), and the subsequent conversion of temporary shares (BTA) into actual shares, including key dates (last day for BTA trading, record date, share availability date) and the resulting change in share capital and total number of shares. This content directly relates to changes in the company's capital structure and financing activities, specifically the finalization of a share issuance/fundraising event. This aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple announcement of a report publication (RPA), as it contains substantive details about the financing outcome.
2022-11-08 Swedish
Förändring av antal aktier i Nanologica AB (publ)
Share Issue/Capital Change Classification · 98% confidence The document is a press release dated October 31, 2022, titled "Förändring av antal aktier i Nanologica AB (publ)" (Change in the number of shares in Nanologica AB (publ)). It explicitly details the outcome of a previously announced rights issue (företrädesemission), stating the resulting increase in the number of shares (from 28,165,826 to 36,146,142) and the corresponding change in share capital. This type of announcement, which reports a change in the total number of outstanding shares due to a financing event (like a rights issue or share issuance), directly corresponds to the 'Share Issue/Capital Change' definition. Therefore, the appropriate filing type code is SHA.
2022-10-31 Swedish
Nanologicas valberedning utsedd inför årsstämman 2023
AGM Information Classification · 95% confidence The document text is a formal announcement in Swedish regarding the composition of the Nomination Committee ('valberedning') for the upcoming Annual General Meeting ('årsstämman') in 2023. It names the committee members, states their representation percentage, and outlines the committee's tasks, including proposing board members and remuneration for the AGM. This content directly relates to the preparatory steps and governance surrounding the Annual General Meeting. While it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI), it is a specific announcement concerning the governance structure leading up to the AGM. Given the options, 'AGM-R' (AGM Information) is the closest fit as it pertains directly to the AGM process, although 'CGR' (Governance Information) is also plausible. However, since the focus is explicitly on the 'valberedning' for the 'årsstämman', AGM-R is the most precise category for this preparatory announcement.
2022-10-20 Swedish
Nanologica tillförs 79,8 MSEK i företrädesemission
Capital/Financing Update Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces the outcome of a rights issue ("nyemission av aktier med företrädesrätt"). It details the amount raised (79.8 MSEK), the subscription rate (85%), and the resulting increase in share capital and number of shares. This type of announcement, detailing fundraising activities, capital structure changes, and the final result of a financing round, directly corresponds to the definition of 'Capital/Financing Update'. It is not a full annual report (10-K), an earnings release (ER) which focuses on operational results, or a proxy statement (PSI). Since it is the primary announcement of the financing event itself, 'CAP' is the most appropriate classification.
2022-10-10 Swedish
Nanologica offentliggör prospekt med anledning av företrädesemission
Capital/Financing Update Classification · 98% confidence The document is titled "Inbjudan till teckning av aktier i Nanologica AB (publ)" (Invitation to subscribe for shares in Nanologica AB (publ)) and details a rights issue ("Företrädesemissionen"). It explicitly mentions the creation and approval of a "Prospekt" (Prospectus) by the Swedish Financial Supervisory Authority ("Finansinspektionen") under the Prospectus Regulation (EU) 2017/1129. A prospectus is a mandatory disclosure document for public offerings of securities. While it contains financial information, its primary purpose is to solicit investment through a capital change event. This aligns best with the 'Capital/Financing Update' (CAP) category, as it is the core document detailing the terms of the share offering and fundraising effort. It is not a standard annual report (10-K), interim report (IR), or just a simple dividend notice (DIV).
2022-09-20 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.